Imaging of novel therapies in Gliblastomas using multiple biomarkers W. Reichardt; Freiburg/DE Glioblastomas still have an extremely poor prognosis up to now and new therapeutic concepts are urgently needed. One of them is Anti-angiogenesis, which has been approved recently and is now under clinical evaluation. Next to edema formation and tumor morphometry, MR imaging can provide a number of vascular characteristics for therapy assessment in the tumors, which could especially provide an early assessment of the therapy. Anti-angiogenic therapy in tumors can be monitored by dynamic contrast enhanced MRI (DCE-MRI) or dynamic susceptibility contrast imaging (DSC-MRI) and vessel size imaging (VSI) to detect changes in tumor microvasculature. DCE-MRI (yielding permeability) is based on the measurement of a concentration time curve after injection of a Gd-based contrast agent (CA), whereas vessel size imaging and DSC-MRI (yielding blood volume) is usually performed with iron-oxide particles. We could show that it is possible to acquire multiple biomarkers to assess therapy response simultaneously in vivo using a single shot gradient echo spin echo (GESE) EPI sequence with only one Gd-CA injection. To account for the typical tumor heterogeneity in gliomas, tumor segmentation was performed prior to the determination of the bloodflow characteristics. The determination of VSI and blood volume measurements using Gd-DTPA has already been demonstrated successfully.